NCT00216528 – A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta) Posted on March 18, 2019 by tsuperadmin -
NCT01314118 – A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease Posted on March 8, 2019 by tsuperadmin -
NCT01105247 – A Phase 1b/2 Fixed-dose Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia Posted on February 19, 2019 by tsuperadmin -
NCT01236391 – Multicenter Phase 2 Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma Posted on February 19, 2019 by tsuperadmin -
NCT01722487 – Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Posted on February 19, 2019 by tsuperadmin -
NCT00060502 – A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer Posted on January 16, 2019 by tsuperadmin -
NCT00086112 – A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy Posted on December 20, 2018 by tsuperadmin -
NCT01050582 – Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Posted on December 20, 2018 by tsuperadmin -
NCT00576732 – Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety Posted on December 20, 2018 by tsuperadmin -
NCT00236379 – A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Posted on December 20, 2018 by tsuperadmin -
The YODA Project